Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 15190122)

1.

In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.

Coffey GP, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder PJ, Pippig S.

J Pharmacol Exp Ther. 2004 Sep;310(3):896-904. Epub 2004 Jun 9.

2.

Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.

Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzales M, Bakshi A, Padilla-Eagar J, Fielder PJ.

Drug Metab Dispos. 2005 May;33(5):623-9. Epub 2005 Jan 26.

3.

The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.

Bonnekoh B, Böckelmann R, Pommer AJ, Malykh Y, Philipsen L, Gollnick H.

Skin Pharmacol Physiol. 2007;20(2):96-111. Epub 2006 Dec 13.

PMID:
17167274
4.

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ.

Pharm Res. 2005 Jul;22(7):1088-100. Epub 2005 Jul 22.

PMID:
16028009
5.

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody.

Clarke J, Leach W, Pippig S, Joshi A, Wu B, House R, Beyer J.

Regul Toxicol Pharmacol. 2004 Dec;40(3):219-26.

PMID:
15546677
6.

Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.

Guttman-Yassky E, Vugmeyster Y, Lowes MA, Chamian F, Kikuchi T, Kagen M, Gilleaudeau P, Lee E, Hunte B, Howell K, Dummer W, Bodary SC, Krueger JG.

J Invest Dermatol. 2008 May;128(5):1182-91. doi: 10.1038/jid.2008.4. Epub 2008 Jan 31.

8.

Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.

Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W.

J Invest Dermatol. 2008 Nov;128(11):2615-24. doi: 10.1038/jid.2008.98. Epub 2008 May 22.

9.

Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody.

Dedrick RL, Walicke P, Garovoy M.

Transpl Immunol. 2002 May;9(2-4):181-6. Review.

PMID:
12180828
10.

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M.

Arch Dermatol. 2002 May;138(5):591-600.

PMID:
12020219
11.

Treatment of hand and foot psoriasis with emphasis on efalizumab.

Kircik L.

Skin Therapy Lett. 2007 Nov;12(9):4-7. Review.

12.

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.

Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, Garovoy M, Kwon P, Walicke P, Dedrick R.

J Clin Pharmacol. 2006 Jan;46(1):10-20. Review.

PMID:
16397279
13.

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.

Lowes MA, Chamian F, Abello MV, Leonardi C, Dummer W, Papp K, Krueger JG.

BMC Dermatol. 2007 Feb 26;7:2.

14.

[The lymphocyte: protagonism in the new era of the biological therapies].

Gutiérrez M, Ruiz Carrascosa JC.

Actas Dermosifiliogr. 2008 Jan;99 Suppl 1:2-8. Review. Spanish.

PMID:
18341848
15.

[Efalizumab].

Descamps V.

Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. Review. French.

PMID:
17053736
16.

Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.

Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, Lee E, Howell K, Bodary S, Dummer W, Krueger JG.

Clin Immunol. 2004 Oct;113(1):38-46.

PMID:
15380528
17.

Efalizumab, a reversible T-cell modulator for psoriasis.

Shear NH, Langley RG, Ho V.

J Cutan Med Surg. 2006;9 Suppl 1:4-9. Review.

PMID:
16633862
18.

Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR.

J Pharmacokinet Biopharm. 1999 Aug;27(4):397-420.

PMID:
10826130
19.

Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.

Bonnekoh B, Pommer AJ, Böckelmann R, Hofmeister H, Philipsen L, Gollnick H.

Skin Pharmacol Physiol. 2007;20(5):237-52. Epub 2007 Jun 22.

PMID:
17587888
20.

Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.

Schön MP.

Clin Dermatol. 2008 Sep-Oct;26(5):509-14. doi: 10.1016/j.clindermatol.2007.10.027. Review.

PMID:
18755369
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk